Following positive clinical trial data, Cambridge-based Genzyme Corp., which has operations in Framingham, has submitted a license application with the U.S. Food and Drug Administration for a leukemia treatment.
Genzyme is working with Bayer HealthCare on the treatment, which is called Campath.
Campath is currently approved for patients who have already received a certain treatment, but have failed therapy.
Now, the company would like the drug to be approved for “first-line treatment” of B-cell lymphocytic leukemia, the most prevalent form of adult leukemia, which affects about 120,000 people in the U.S. and Europe.
